Read our HLTH special report in collaboration with FINN Partners on Clinical Strength in Digital Health.
This HLTH special report is based on our report Global Digital Health Innovation Thematic Report on Clinical Strength in Digital Health with additional insights and comments from industry leaders and a special foreword from Cheryl Cheng, Founder & CEO at Vive Collective.
While a great idea and good business acumen have scaled strong Digital Health companies over the past decade, there is a shift in focus to proof points, with Clinical Strength being a priority data point. Galen Growth first published its industry-leading research report in 2022 looking at the Clinical Strength of a Digital Health venture by evaluating a venture’s clinical trials, regulatory filings, and peer-reviewed publications.
This report dives deep into the Global Digital Health ecosystem to demonstrate the importance of proof points for ventures to attract funding, types of products that have proven Clinical Strength, as well as the growth of proof points and its impact on venture success.
The “Global Digital Health Innovation Thematic Report on Clinical Strength in Digital Health” report includes data on the following companies: CyMedica, Neurophet, AstraZeneca, Roche, Novartis, NHS, Mayo Clinic, Tempus, Lunit, 23andME, SOPHiA Genetics, Helix, HeartFlow, Idoven, Health.io, Saluda Medical, Synaptive Medical, Augmedics, Spect, Owlstone Medical, Mojo Vision, Eargo, Finni Health, Densitas, Hygieia, Selfapy, Perspectum, Castor, Eyetelligence, SigTuple Technologies, The Intellect Company, Droobi Health, Neteera Technologies, Distalmotion, Aledade, Cognito Therapeutics, EOFlow, Lucira, Winterlight Labs, Limbix, XRHealth, Medtronic, Pfizer, Cambridge Cognition, Big Health, Geisinger, Chugai Pharmaceutical, MD Anderson Cancer Center, Novo Nordisk, Point32Health, Freenome, Biofourmis, Generate Biomedicines, Diabeloop, Valera Health
Galen Growth is pleased to share with you our latest insights on the Clinical Strength of Digital Health ventures. We define the boundaries of this important topic and connect the importance of proof points for funding, product development, and partnerships. Our analysis focuses on private ventures and includes ecosystem growth, most active partners, regulatory approvals and venture funding.
HealthTech Alpha, a Galen Growth proprietary solution, and the global leading Digital Health private market data, intel and insights platform powers this report!
Our Premium Reports are specialized reports that are only available to active users with HealthTech Alpha Pro and HealthTech Alpha Enterprise accounts and are provided at no additional cost.
Galen Growth’s proprietary platform, HealthTech Alpha, provides the data source for this report. Corporate Business Development, Business Intelligence, and Digital Health Partnership teams worldwide prefer HealthTech Alpha, the world’s most-trusted Digital Health data, intel, and insights platform. Visit https://www.healthtechalpha.com to learn more about our data or https://www.galengrowth.com research for our reports.
Founded in 2016 by Digital Health experts, Galen Growth empowers global Fortune 500 companies, institutional investors, and promising Digital Health ventures to fast track their digital health strategy to create significant financial and social values. To find out more, visit https://www.galengrowth.com
|ABOUT GALEN GROWTH|
|INTRODUCTION: 10 pages, 5 charts, 2 tables|
|ECOSYSTEM INSIGHTS: 11 pages, 11 charts, 2 tables|
|CLUSTER FOCUS: 4 pages, 3 charts, 1 table|
|THERAPEUTIC FOCUS: 4 pages, 4 charts, 1 table|
|INVESTMENT INSIGHTS: 3 pages, 3 charts, 2 tables|
|DEEP DIVES: 15 pages, 16 charts, 4 tables|
|NOTEWORTHY: 3 pages, 3 tables|